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Abstract
Background The presence of lymph node metastasis (LNmets) is a poor prognostic factor in oesophageal cancer (OeC) 
patients treated with neoadjuvant chemoradiotherapy (nCRT) followed by surgery. Tumour regression grade (TRG) in LNmets 
has been suggested as a predictor for survival. The aim of this study was to investigate whether TRG in LNmets is related 
to their location within the radiotherapy (RT) field.
Methods Histopathological TRG was retrospectively classified in 2565 lymph nodes (LNs) from 117 OeC patients treated 
with nCRT and surgery as: (A) no tumour, no signs of regression; (B) tumour without regression; (C) viable tumour and 
regression; and (D) complete response. Multivariate survival analysis was used to investigate the relationship between LN 
location within the RT field, pathological TRG of the LN and TRG of the primary tumour.
Results In 63 (54%) patients, viable tumour cells or signs of regression were seen in 264 (10.2%) LNs which were classified 
as TRG-B (n = 56), C (n = 104) or D (n = 104) LNs. 73% of B, C and D LNs were located within the RT field. There was a 
trend towards a relationship between LN response and anatomical LN location with respect to the RT field (p = 0.052). Mul-
tivariate analysis showed that only the presence of LNmets within the RT field with TRG-B is related to poor overall survival.
Conclusion Patients have the best survival if all LNmets show tumour regression, even if LNmets are located outside the 
RT field. Response in LNmets to nCRT is heterogeneous which warrants further studies to better understand underlying 
mechanisms.
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Abbreviations
LN-TRG  Tumour regression in lymph nodes
nCRT  Neoadjuvant chemoradiotherapy
LNs  Lymph nodes
RT  Radiotherapy
OeC  Oesophageal cancer
TRG  Tumour regression grade
ENI  Elective lymph node irradiation
LNmets  Lymph node metastasis
LN  Lymph node
GTV  Gross tumour volume
CTV  Clinical target volume
PTV  Planning target volume
Introduction
The current standard treatment for patients with locally 
advanced resectable oesophageal cancer (OeC) with cura-
tive intent is multimodal therapy, either with neoadjuvant 
chemoradiotherapy (nCRT) according to the CROSS trial or 
combination chemotherapy according to the OE02 trial, both 
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followed by surgical resection [1–3]. Although the addition 
of neoadjuvant treatment offers a survival benefit compared 
to surgery alone, survival remains poor with 5-year overall 
survival rates varying between 23 and 47% [3, 4].
A pathological complete response (tumour regression 
grade [TRG] 1 according to Mandard) of the primary tumour 
in the resected specimen has been reported in up to 29% of 
OeC patients treated with nCRT [2, 5]. On the other hand, 
38% of OeC patients have limited or no signs of response 
(TRG 3-5). TRG of the primary tumour has been suggested 
as a prognostic factor [6]. However, presence of lymph node 
metastasis (LNmets), their anatomical location and TRG 
in LNmets (LN-TRG) are potentially better predictors of 
patient’s survival than TRG of the primary tumour [7–10]. 
Kadota et al. illustrated the relationship between nCRT 
response in lymph nodes (LNs) and prognosis in patients 
with OeC [10]. Furthermore, Philippron et al. showed that 
even if no viable tumour is found in LNs but LNs show signs 
of tumour regression, survival is worse compared to patients 
with truly negative LNs (no evidence of tumour or tumour 
regression) [11]. These studies suggest that LN-TRG after 
nCRT and location of LNmets in relation to the radiation 
field may be important factors for OeC patient’s prognosis. 
However, previous studies did not evaluate whether there 
is a relationship between LN location with respect to the 
radiotherapy (RT) field and LN-TRG.
Elective lymph node irradiation (ENI) and two-field lym-
phadenectomy are commonly used in OeC patient manage-
ment to prevent local recurrence and distant metastases. Cur-
rent ENI guidelines recommend focusing elective irradiation 
on locoregional LN stations; however, the optimal extent is 
still under debate [12, 13].
We hypothesized that all LNmets located within the radi-
otherapy (RT) field will show evidence of tumour regres-
sion, confirming current clinical practice [1].
The aim of this study was to investigate the pathological 
TRG in individual LNmets and relate the results to their 
location within the RT field in a series of OeC patients 
treated with nCRT followed by surgical resection.
Materials and methods
Patients and treatment
This research has been approved by the Medical Ethical 
Commission of the Zuyderland Medical Center (Heerlen, 
NL). All patients diagnosed with oesophageal cancer (OeC) 
between 2010 and 2016 at the Zuyderland Medical Center 
(Heerlen, The Netherlands) with clinical TNM 7th edition 
stage IB–IIIC disease treated with neoadjuvant chemora-
diotherapy (nCRT) followed by surgery were included in 
this study. Clinical assessment according to the Dutch OeC 
guidelines included fluorodeoxyglucose positron emission 
tomography (FDG PET/CT) scanning [14]. Approximately 
6–10 weeks after completion of nCRT, a re-evaluation PET/
CT scan was performed to assess radiological response to 
therapy and rule out presence of distant metastatic disease. 
Most patients were treated according to the CROSS trial 
schedule [2]. Depending on primary tumour location and 
patient performance status either a minimally invasive tran-
shiatal oesophagogastrectomy including a one-field low 
mediastinal lymph node (LN) dissection, or a minimal inva-
sive transthoracic approach with Ivor-Lewis-type resection 
and a two-field LN dissection was performed. All patients 
had an oesophageal reconstruction using the stomach.
Radiotherapy planning
A respiratory-gated 4D CT scan was used for RT planning 
purposes and the following regions of interest were deline-
ated using all diagnostic information available: the gross 
tumour volume (GTV) defined as the macroscopic outline 
of the primary tumour and any pathological LNs if applica-
ble; the clinical target volume (CTV) defined as the GTV 
plus a radial margin of 0.5 cm for LNs or 1 cm for primary 
tumour, a 3 cm margin in proximal and distal direction and 
inclusion of elective regional LN regions [12]; the planning 
target volume (PTV) margin added to account for day-to-day 
variation in patient positioning and breathing movements. 
RT was planned to ensure that 99% of the PTV received 
95% of the nominal dose of 41.4 Gy, while conforming to 
the dose constraints of the organs-at-risk (e.g., lungs, heart, 
and spinal cord). Most patients were radiated 5 days per 
week in fractions of 1.8 Gy, up to a total of 23 fractions. 
Concurrently, patients received weekly carboplatin (doses 
titrated to achieve an area under the curve of 2 mg per mil-
liliter per minute) and paclitaxel (50 mg/m2 of body-surface 
area) for 5 weeks [2]. A minority of patients were treated 
with 28 × 1.8 Gy.
Pathology
The surgeon marked the anatomical location of individual 
LN stations with different coloured beads in the resected 
specimen according to Casson et al. [15, 16]. In the his-
topathology laboratory, the fatty tissue was dissected per 
marked LN station and searched for LNs. All LNs were 
completely embedded separately by LN station. Tissue 
was processed into paraffin blocks as per standard proto-
col. Histopathological examination of the Haematoxylin/
Eosin (HE) stained slides was performed by experienced 
gastrointestinal pathologists. TNM classification 7th ed. 
was used for tumour staging, grade of differentiation 
was determined according to the WHO criteria, and the 
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regression of the primary tumour was assessed using the 
tumour regression grading system according to Mandard 
[5, 17, 18].
For the current study, all HE slides from all patients 
were retrieved retrospectively from the pathology archive 
and scanned at 20 × magnification using a Panoramic 250 
scanner (3DHistech, Budapest, Hungary). Scanned slides 
with LNs were identified, reviewed and classified accord-
ing to Martin-Romano et al. by at least two observers as: 
TRG-A: ‘true-negative’ LN without evidence of tumour or 
tumour regression; TRG-B: LN with viable tumour with-
out evidence of tumour regression (no fibrosis, no mucin 
pools); TRG-C: LN with viable tumour and evidence of 
tumour regression (fibrosis or mucin pools or both); TRG-
D: LN without viable tumour and evidence of tumour 
regression (fibrosis or mucin pools or both) interpreted 
as ‘complete tumour regression’ [19] (Fig. 1). Patients 
with only TRG-A LNs were classified as ‘true_ypN0’; 
while, patients with only TRG-D LNs were classified as 
‘complete responders’. All other patients were classified 
as ‘incomplete responders’ (see Table 1).
Data collection and statistics
Patients were followed up according to standard clinical 
practice in referring hospitals. Overall survival (OS) time 
was defined as the time from the last RT fraction to the date 
of death or last follow-up. Date of death was available from 
the Dutch population register, and median follow-up time 
was determined using the ‘inverse Kaplan–Meier’ method 
[20]. Patient and tumour characteristics (sex, age, tumour 
location and clinical TNM stage) were retrieved from hos-
pital medical records. The relationship between patient and 
tumour characteristics and LN-TRG was investigated using 
the Chi-square test for categorical variables or single-factor 
ANOVA for continuous variables.
Based on the maps published by Casson et al., the ana-
tomical location of resected LNs was determined using the 
surgery and histopathology reports [15, 16]. Planning CT 
Fig. 1  a ‘True-negative’ LN 
without evidence of tumour or 
tumour regression. b LN with 
viable tumour no regression 
(class B), c LN with viable 
tumour (circled) and regression 
(class C), d LN with regression 
no viable tumour (class D)
Table 1  Classification of patients in relation to the tumour regression (TRG) seen in their lymph nodes (LN)
Class Definition Classification
A ‘True-negative’ LN without evidence of tumour or tumour regression true_ypN0
B LN with viable tumour without evidence of tumour regression (no fibrosis, no mucin pools) Incomplete responders
C LN with viable tumour and evidence of tumour regression (fibrosis or mucin pools or both) Incomplete responders
D LN without viable tumour and evidence of tumour regression (fibrosis or mucin pools or both) Complete responders
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scans, RT fields and tumour contours were retrospectively 
reviewed by two experienced radiation oncologists. Based 
on anatomical landmarks, individual anatomical LN stations 
were categorized as being ‘inside’ or ‘outside’ of the RT 
field/PTV.
Baseline characteristics were compared between  the 
three LN-TRG groups. The relationship between patho-
logical parameters and LN-TRG groups was only analyzed 
for patients with either TRG-B, TRG-C or TRG-D lymph 
nodes, thus excluding ‘true_ypN0 patients’ from the analy-
ses. The same cohort was used in the multivariate survival 
analysis. The relationship between LN location within the 
RT field (yes/no), pathological TRG of individual LNs, pri-
mary tumour TRG and resection margin status was analyzed 
using multivariate Cox regression analysis. One patient was 
excluded from the survival analysis due to missing data. 
P-values less than 0.05 were considered significant.
Results
In total, 117 patients with clinical stage IB–IIIC oesophageal 
cancer were included in this study. At the time of analysis, 
60 patients were still alive; their median follow-up time was 
37 months (95%CI: 29–44 months). Median (range) time 
between end of nCRT and surgery was 10 weeks (IQR: 
9–12 weeks). Clinical characteristics of the patient cohort 
are provided in Table 2.
Resected lymph nodes
A total of 2565 LNs was resected, with a median (range) of 
20 LNs per patient (6–51 LNs). LNmets were most com-
monly found in LN stations 17–20 (left gastric artery, com-
mon hepatic artery, splenic artery, and celiac axis). For a 
summary of the frequency of LNs and LNmets per resected 
LN station, see supplementary table S1. Histopathological 
characteristics of the resection specimens are available in 
Table 3.
Table 2  Baseline patient characteristics
cT-stage clinical T-stage, according to 7th edition TNM classification, cN-stage clinical N-stage, according to 7th edition TNM classification, 
GEJ gastroesophageal junction 
Baseline characteristics True_ypN0 (n = 54) Complete LN 
responders (n = 17)
Incomplete LN 
responders (n = 46)
All (n = 117) p values
Age, median (range) years 65 (41–78) 63 (43–75) 65 (47–77) 65 (41–78) 0.588
Gender
 Male 39 (72%) 14 (82%) 41 (89%) 94 (80%) 0.103
 Female 15 (28%) 3 (18%) 5 (11%) 23 (20%)
Histology
 Adenocarcinoma 42 (78%) 15 (88%) 37 (80%) 94 (80%) 0.639
 Squamous cell carcinoma 12 (22%) 2 (12%) 9 (20%) 23 (20%)
Tumour location
 Proximal–middle 9 (17%) 1 (6%) 2 (4%) 12 (10%) 0.055
 Distal 23 (43%) 13 (76%) 24 (52%) 60 (51%)
 GEJ–cardia 22 (41%) 3 (18%) 20 (43%) 45 (38%)
cT-stage
  T1 – – 1 (2%) 1 (1%) 0.172
 T2 14 (26%) 2 (12%) 6 (13%) 22 (19%)
 T3 39 (72%) 14 (82%) 37 (80%) 90 (77%)
 T4 1 (2%) – 2 (4%) 3 (3%)
 Tx – 1 (6%) – 1 (1%)
cN-stage
 N0 21 (39%) 5 (29%) 3 (7%) 29 (25%) 0.033
 N1 16 (30%) 6 (35%) 21 (46%) 43 (37%)
 N2 12 (22%) 3 (18%) 11 (24%) 26 (22%)
 N3 5 (9%) 3 (18%) 10 (22%) 18 (15%)
 Nx – – 1 (2%) 1 (1%)
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Relationship between tumour regression in lymph 
nodes and overall survival
In 54 (46%) patients, none of the resected LNs contained 
tumour or had signs of tumour regression (i.e. all LNs 
were classified as TRG-A nodes). These patients were 
classified as ‘true_ypN0’. Overall survival (OS) of the 
‘true_ypN0’ patients was significantly longer compared 
to all other patients (p = 0.002), with median overall sur-
vival of 52 months and 19 months, respectively, see Fig. 2.
In 63 (54%) patients, a total of 264 LNs contained 
tumour with or without evidence of regression: 56 (21%) 
TRG-B, 104 (39%) TRG-C and 104 (39%) TRG-D. 17 
(27%) patients were classified as complete LN responders 
as they had only TRG-D LNs, and 46 (73%) as ‘incomplete 
LN responders’ as they had vital tumour in at least one LN. 
There was no difference in OS between true_ypN0 patients 
(n = 54) and patients in the complete LN responder group 
(n = 17) (Fig. 2, p = 0.969). There was a significant dif-
ference in OS between ypN + patients and true_ypN0/
complete LN responders (Fig. 2, p < 0.001, p = 0.017, 
respectively).
Relationship between clinicopathological data 
and patients grouped by TRG in lymph nodes
As can be seen in Table 2, baseline clinical characteristics 
including age, sex, and histology were similar between the 
Table 3  Pathological patient characteristics
TRG tumour regression grade, according to Mandard classification, ypT-stage pathological T-stage, according to TNM 7th edition, ypN-stage 
pathological N-stage, according to 7th edition TNM classification, LN lymph nodes
*Comparison was done between the groups ‘responders’ and ‘non-responders’
Baseline characteristics True_ypN0 (n = 54) Complete LN 
responders (n = 17)
Incomplete LN 
responders (n = 46)
All (n = 117) p values*
Pathologic response primary tumour
 TRG 1 14 (26%) 6 (35%) 7 (15%) 27 (23%) 0.056
 TRG 2 12 (22%) 2 (12%) 7 (15%) 21 (18%)
 TRG 3 12 (22%) 5 (29%) 9 (20%) 26 (22%)
 TRG 4 11 (20%) 3 (18%) 17 (37%) 31 (26%)
 TRG 5 3 (6%) – 6 (13%) 9 (8%)
 TRG x 2 (4%) 1 (6%) 0 (%) 3 (3%)
ypT-stage
 T0 14 (26%) 6 (35%) 7 (15%) 27 (23%) 0.042
 T1 9 (17%) 3 (18%) 4 (9%) 16 (14%)
 T2 15 (28%) 5 (29%) 11 (24%) 31 (26%)
 T3 16 (30%) 3 (18%) 24 (52%) 43 (37%)
ypN-stage
 N0 54 (100%) 17 (100%) – 71 (61%) < 0.001
 N1 – – 26 (57%) 26 (22%)
 N2 – – 12 (26%) 12 (10%)
 N3 – – 8 (17%) 8 (7%)
ypTNM vs cTNM stage
 Down 54 (100%) 15 (88%) 23 (50%) 92 (79%) < 0.001
 Same 0 (%) 1 (6%) 17 (37%) 18 (15%)
 Up 0 (%) 0 (%) 5 (11%) 5 (4%)
 N/A 0 (%) 1 (6%) 1 (2%) 2 (2%)
Circumferential resection margin
 R0 51 (94%) 16 (94%) 39 (85%) 106 (91%) 0.167
 R0 (margin < 1 mm) 1 (2%) 0 (%) 3 (7%) 4 (3%)
 R1 1 (2%) 1 (6%) 4 (9%) 6 (5%)
 N/A 1 (2%) 0 (%) 0 (%) 1 (1%)
Resected LN, n median (range) 19 (6–38) 20 (11–38) 21 (7–51) 20 (6–51) 0.693
Resected stations, n median (range) 5 (1–9) 6 (2–9) 5 (1–8) 5 (1–9) 0.033
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patients classified as ‘true_ypN0’, ‘complete LN responders’ 
or ‘incomplete LN responders’. For the following analyses, 
‘true_ypN0’ patients were excluded, leaving 63 patients 
for analysis. There was a significant relationship between 
patients classified as ‘complete LN responders’ or ‘incom-
plete LN responders’ and ypT-stage (p = 0.042), number of 
resected LN stations (p = 0.033) and anatomical location of 
the resected LNs (p = 0.035). There was no significant rela-
tionship between ‘complete LN responders’ or ‘incomplete 
LN responders’ and total number of resected LNs (p = 0.693) 
and TRG of the primary tumour (p = 0.056).
Tumour regression in lymph nodes, location 
within the radiotherapy field and survival
In depth analysis of the LNs within/outside the RT field 
focused on the 63 patients with LNmets or LNs with signs of 
regression, i.e., the ‘complete LN responders’ and ‘incom-
plete LN responders’. 193 (73%) of the 264 LNmets were 
found to be located within the planned RT field. 13 of the 
264 (5%) LNs from 9 patients were located outside the RT 
field. Four of these LNs were TRG-B LNs, 8 TRG-C LNs 
and one TRG-D LN. In 58 LNs (22%), the exact anatomical 
LN location and, thus, the relation to the RT field could 
not be ascertained, these were excluded from the analysis. 
In 7 (78%) of the 9 patients with LNmets outside the RT 
field, these were located paratracheal/subcarinal with the 
primary tumour located in the distal oesophagus (2 patients) 
or at the gastroesophageal junction (5 patients). The other 2 
(22%) patients had a primary tumour above the diaphragm 
with LNmets outside the RT field in the abdominal LN sta-
tions. The RT plan of a patient with a LN showing complete 
regression outside the RT field is illustrated in Fig. 3. There 
was no significant relationship between LN-TRG and ana-
tomical location of the LN within the RT field (p = 0.052, 
supplementary table S2), probably related to small number 
of patients. Outside the RT field, 69% of LNmets had signs 
of tumour regression (Fig. 4).
Univariate Cox regression revealed a significant relation-
ship between OS and the number of TRG-B LNs located 
within the RT field [hazard ratio (HR) 1.1, 95% CI 1–1.3] 
(table S3). Patients with TRG-B LNs within the RT field 
had a significantly shorter OS than patients without TRG-B 
LNs within the RT field, 14 and 29 months, respectively 
(p < 0.001) (Fig. 5).
Fig. 2  Kaplan–Meier curve 
showing that overall survival for 
ypN0 patients and LN respond-
ers differs significantly from LN 
non-responders
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Univariate analysis comparing TRG of the primary 
tumour showed that patients with TRG-1 or TRG-2 in the 
primary tumour had significantly better survival compared 
to patients with TRG-3, TRG-4 or TRG-5 in the primary 
tumour (p = 0.009).
Multivariate overall survival analysis
In multivariate analysis, resection margin status (p = 0.04) 
and presence of TRG-B LNs in the RT field (p = 0.01) were 
the only factors significantly related to survival (for details, 
see Table 4). The regression grade of the primary tumour 
was not related to survival in multivariate analysis (p = 0.69).
Heterogeneity in lymph node TRG 
Notably, in some patients, a highly heterogeneous LN-TRG 
was observed. Five (8%) patients had LNs within all three 
LN-TRG categories (B, C, D) and another 27 (42%) patients 
had LNs within two of the three categories. In two patients, 
TRG-D LNs and TRG-B LNs were observed within the 
same LN station.
Discussion
Major pathological response in the primary tumour has 
been related to better overall survival in oesophageal cancer 
(OeC) patients [6]. However, tumour regression (TRG) in 
LNmets might be a better predictor of survival than patho-
logical response in the primary tumour [12]. In this study of 
OeC patients treated with neoadjuvant chemoradiotherapy 
(nCRT) followed by surgery, we aimed to analyze TRG in 
LNmets (LN-TRG) in relation to the LN location within the 
radiotherapy (RT) field and the relationship between LN-
TRG and overall survival (OS).
We showed that patients without LNmets and without 
evidence of LN-TRG, e.g., the ‘true_ypN0’ patients, had a 
significantly better OS compared to patients with LNmets. 
Also, patients with evidence of a complete response in their 
LNs had a better survival than ypN+ patients. Patients in 
the ‘incomplete responder’ group with one or more LNmets 
without any sign of tumour regression (TRG-B LNs) had 
poorer survival than patients in this group with LNmets all 
showing signs of regression (TRG-C LNs) which was also 
confirmed in multivariate analysis. These findings support 
previous findings that LN-TRG might predict OeC patient 
survival [12]. Our study results suggest that LN-TRG 
might be related to primary tumour response, a finding 
which one might expect but to the best of our knowledge has 
not been reported in the literature. The presence of TRG-B 
LNs was significantly related to survival in multivariate 
analysis, when the TRG of the primary tumor was included 
in the model. Our finding that LN-TRG seems to be a bet-
ter prognostic factor after chemoradiotherapy than TRG in 
the primary tumour validates results reported previously by 
Davies et al. and Urakawa et al. [21, 22].
After nCRT, 40% of OeC patients had evidence of 
LNmets, which is much lower than at time of diagnosis 
when 75% of the patients was staged as cN+. This differ-
ence can be explained by the complete LN responders (15% 
of all patients) and the fact that over 60% of the true_ypN0 
patients were diagnosed as cN+ prior to treatment suggest-
ing a clinical overdiagnosis of N+ patients. This could be 
due to false-positive detection in radiological imaging or an 
Fig. 3  Dose distribution of a 
representative patient with a 
cT3N2M0 adenocarcinoma in 
the gastroesophageal junc-
tion. In the resected specimen 
a lymph node with complete 
regression was detected in the 
left upper paratracheal region 
(2L), indicated in orange
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incorrect pathological N-stage due to an incomplete lym-
phadenectomy [23, 24].
We hypothesized that all LNmets within the RT field 
would show some degree of tumour regression; whereas, 
this would not apply to LNmets outside the RT field. How-
ever, our results do not entirely confirm this hypothesis, as 
there seems to be a relationship between the location of the 
LNmets and the regression seen in the LN. But this result 
is only borderline significant in our study, probably due 
to small number of patients. The tumour regression seen 
in LNmets outside the RT field could be explained by the 
concomitant administered systemic chemotherapy. This 
chemotherapy will reach the LNs outside the RT field and 
it is known, from the OE02 trial, that patients treated with 
chemotherapy have nodal response [11]. Another possibility 
is that LNs outside the RT field show tumour regression due 
to a systemic immunological response to the tumour, known 
as the abscopal effect [25]. However, the fact that LNs of 
the same patient found within the same LN station can have 
completely different responses to nCRT was surprising. We 
hypothesize that this might be due to a difference in blood 
supply, allowing more chemotherapy to reach the LNmet 
with the better blood supply. Second, it could be due to 
tumour clonality or be related to the immune cell population 
present in the lymph node. It is well known that cancer cells 
can be highly heterogeneous even within patients [26, 27]. 
Clonality can be a major factor contributing to resistance 
against neoadjuvant therapies [28]. Although we have cur-
rently no evidence for this, it might be that different clones 
of the tumour with different resistance patterns populated 
the LNs located within the same LN station.
Our study has some limitations. As treatment of OeC 
patients changed with the publication of the CROSS trial 
results, we do not have a contemporary group of non-neo-
adjuvant-treated OeC patients. So, we were unable to assess 
whether LNs can show fibrosis even if there has been no 
neoadjuvant treatment. Assessment with certainty, whether 
LNs were located in or outside the RT field, was difficult in 
borderline cases. However, the PTV was used as uncertainty 
margin which compensates this partly. From 24% of the 
resected LNs, the exact anatomical location was not trace-
able as they were located in undefined fatty tissue attached to 
the resected specimen. However, as most were found closely 
to the tumour, we assume that most of them were radiated. 
Unfortunately, data on recurrence pattern were not available 
to us for analysis in the current study. Urakawa et al. have 
shown that in the metastatic setting, the response of the LN 
to chemotherapy can predict long-term survival and recur-
rence [22]. They found that LN non-responders presented 
more often with lymphatic and/or haematogenous recurrence 
and dissemination compared to LN responders. Results that 
are statistically not significant can be a consequence from 
the low number of participants resulting in a lack of power, 
future studies including more patients are needed to confirm 
these results.
In conclusion, this study showed a number of novel poten-
tially clinically relevant findings. First of all, if tumour-posi-
tive LNs are found, the more tumour regression LNs show, 
the better the survival. Second, LNs outside the RT field 
can show tumour regression and even though a LN has been 
irradiated with the full dose, it might not show any response. 
Third, TRG in the LN has been shown to be related to TRG 
in the primary tumour. And lastly, LN-TRG within a patient 
can be extremely heterogenous, even LNs within the same 
LN station of the same patient can respond differently. Given 
the low incidence of LNmets outside the RT field, mainly in 
remote regions, this study provides no evidence for enlarging 
the RT field. However, further research is needed to detect 
LNmets more accurately during clinical staging and to better 
understand the heterogeneous LN-TRG seen in OeC patients.
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